Management of Acquired Long QT Syndrome

Initial Management

The American College of Cardiology recommends immediately discontinuing all QT-prolonging medications and correcting electrolyte abnormalities, particularly maintaining serum potassium >4.0 mmol/L and normalizing magnesium levels (≥2.0 mmol/L), for patients with acquired long QT syndrome 1, 3
Administer intravenous magnesium sulfate (2g) regardless of serum magnesium level for patients with torsades de pointes or significant QT prolongation, as recommended by the American College of Cardiology and Circulation 1, 2, 3

For hemodynamically unstable torsades de pointes, perform immediate non-synchronized defibrillation, as recommended by Circulation 2, 3
For bradycardia-induced torsades de pointes, implement temporary overdrive pacing with rates of 90-110 bpm, as recommended by Circulation 2, 3

Beta-blockers may be beneficial in reducing arrhythmia recurrence, particularly when QT prolongation is associated with myocardial ischemia, according to the American College of Cardiology 1, 5, 3
Consider left cardiac sympathetic denervation in high-risk patients with recurrent torsades de pointes despite standard measures, as recommended by the American College of Cardiology 1, 6

Avoid all QT-prolonging medications unless absolutely necessary, and maintain normal electrolyte balance, especially during situations that promote depletion, as recommended by the American College of Cardiology 1, 3